Related Experiment Video
Updated: May 9, 2026
07:08
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Small bowel adenocarcinomas--existing evidence and evolving paradigms
Kanwal Raghav1, Michael J Overman
1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Centre, Unit #426, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Nature Reviews. Clinical Oncology
|July 31, 2013
Summary
Small bowel adenocarcinomas are rare gastrointestinal cancers with unique challenges. Advances in diagnosis and molecular understanding offer hope for developing targeted therapies and improved treatment strategies.
Area of Science:
- Gastroenterology
- Oncology
- Molecular Biology
Background:
- Small bowel adenocarcinomas are rare, comprising 3% of GI malignancies and a third of small bowel cancers.
- Their rarity poses challenges in molecular understanding, diagnosis, and treatment.
- Distinct from large bowel adenocarcinomas, they require specific management approaches.
Purpose of the Study:
- To review the current evidence-based management of small bowel adenocarcinoma.
- To highlight diagnostic and therapeutic challenges associated with these rare tumors.
- To explore evolving paradigms and future directions in treatment.
Main Methods:
- Review of current literature on small bowel adenocarcinoma.
- Analysis of diagnostic advancements (imaging, endoscopy).
- Evaluation of therapeutic strategies including surgery and chemotherapy.
Main Results:
- Improved diagnostic accuracy with cross-sectional imaging, enteroscopy, and capsule endoscopy.
- Surgical resection is the primary treatment for locoregional disease.
- Chemotherapy (fluoropyrimidine, oxaliplatin-based) shows benefit in metastatic settings.
Conclusions:
- Small bowel adenocarcinomas are distinct entities requiring tailored therapeutic strategies.
- Molecular characterization is crucial for understanding pathogenesis and developing targeted therapies.
- Multi-institutional collaboration is essential for advancing research and clinical trials.
